Advertisement

NeuroMolecular Medicine

, Volume 18, Issue 3, pp 396–414 | Cite as

Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs

  • Mitchell K. P. Lai
  • Wee Siong Chew
  • Federico Torta
  • Angad Rao
  • Greg L. Harris
  • Jerold Chun
  • Deron R. HerrEmail author
Review Paper

Abstract

Sphingolipids (SPs) comprise a highly diverse class of lipids that serve biological roles both as structural components of cell membranes and as mediators of cell signaling. Pharmacologic and genetic manipulation of SPs and their signaling systems have underscored their importance in most biological processes, including central nervous system development and function. Likewise, perturbations of SP accumulation or signaling have been associated with a number of disease states, such as neural tube defects, neuroinflammation, stroke, and dementia. SPs can be endogenously synthesized de novo, and their metabolism is a well-regulated process, so their value as nutraceuticals has not been scrutinized. However, there is evidence that sphingolipid-rich diets can affect lipid homeostasis, and several mycotoxins are SP analogs that are known to cause profound derangement of SP metabolism or signaling. Furthermore, plants and invertebrates have SP species that are not present in mammals. Several of these have been shown to induce biological responses in mammalian cells. These findings suggest that dietary intake of SPs or SP analogs may have significant effects on human health or disease outcome. This manuscript provides an overview of SP metabolism and signaling, their perturbations in neurological diseases, as well as potential impacts of modulating this system in the brain.

Keywords

Sphingolipid Fingolimod Nutraceutical Sphingosine 1-phosphate receptor Ceramide Review 

Notes

Compliance with Ethical Standards

Conflict of interest

D.R.H. and G.L.H. have received consulting fees or grant support from Expression Drug Designs, LLC and Bayer Healthcare. J.C. has received honoraria, consulting fees and/or grant support from: Abbott, Amira Pharmaceuticals, Biogen-Idec, Celgene, GlaxoSmithKline, Johnson and Johnson, Merck, Mitsubishi Tanabe Pharma Corporation, Novartis, Ono Pharmaceutical Co., Pfizer and Taisho Pharmaceutical Co. M.K.P.L., W.S.C., F.T., and A.R. have no financial relationships to declare.

References

  1. Abbas, H. K., Duke, S. O., Merrill, A. H, Jr., Wang, E., & Shier, W. T. (1998). Phytotoxicity of australifungin, AAL-toxins and fumonisin B1 to Lemna pausicostata. Phytochemistry, 47(8), 1509–1514. doi: 10.1016/S0031-9422(97)00781-4.CrossRefGoogle Scholar
  2. Abeytunga, T. U. (2015). Occurrence, structure elucidation, biosynthesis, functions and synthesis of sphingadienes. Mini-Reviews in Organic Chemistry, 12(3), 282–292.CrossRefGoogle Scholar
  3. Abeytunga, D. T., Glick, J. J., Gibson, N. J., Oland, L. A., Somogyi, A., Wysocki, V. H., et al. (2004). Presence of unsaturated sphingomyelins and changes in their composition during the life cycle of the moth Manduca sexta. Journal of Lipid Research, 45(7), 1221–1231. doi: 10.1194/jlr.M300392-JLR200.PubMedCrossRefGoogle Scholar
  4. Abeytunga, D. T., Oland, L., Somogyi, A., & Polt, R. (2008). Structural studies on the neutral glycosphingolipids of Manduca sexta. Bioorganic Chemistry, 36(2), 70–76. doi: 10.1016/j.bioorg.2007.10.002.PubMedCrossRefGoogle Scholar
  5. Aida, K., Kinoshita, M., Sugawara, T., Ono, J., Miyazawa, T., & Ohnishi, M. (2004). Apoptosis inducement by plant and fungus sphingoid bases in human colon cancer cells. Journal of Oleo Science, 53, 503–510.CrossRefGoogle Scholar
  6. Akahoshi, N., Ishizaki, Y., Yasuda, H., Murashima, Y. L., Shinba, T., Goto, K., et al. (2011). Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2. Epilepsy & Behavior, 22(4), 659–665. doi: 10.1016/j.yebeh.2011.09.002.CrossRefGoogle Scholar
  7. Aldahmesh, M. A., Mohamed, J. Y., Alkuraya, H. S., Verma, I. C., Puri, R. D., Alaiya, A. A., et al. (2011). Recessive mutations in ELOVL4 cause ichthyosis, intellectual disability, and spastic quadriplegia. American Journal of Human Genetics, 89(6), 745–750. doi: 10.1016/j.ajhg.2011.10.011.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Arana, L., Gangoiti, P., Ouro, A., Trueba, M., & Gomez-Munoz, A. (2010). Ceramide and ceramide 1-phosphate in health and disease. Lipids in Health and Disease, 9, 15. doi: 10.1186/1476-511X-9-15.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Aureli, M., Grassi, S., Prioni, S., Sonnino, S., & Prinetti, A. (2015). Lipid membrane domains in the brain. Biochimica et Biophysica Acta, 1851(8), 1006–1016. doi: 10.1016/j.bbalip.2015.02.001.CrossRefPubMedGoogle Scholar
  10. Aytan, N., Choi, J. K., Carreras, I., Brinkmann, V., Kowall, N. W., Jenkins, B. G., et al. (2016). Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer’s disease. Scientific Reports, 6, 24939. doi: 10.1038/srep24939.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bajjalieh, S. M., Martin, T. F., & Floor, E. (1989). Synaptic vesicle ceramide kinase. A calcium-stimulated lipid kinase that co-purifies with brain synaptic vesicles. Journal of Biological Chemistry, 264(24), 14354–14360.PubMedGoogle Scholar
  12. Bandhuvula, P., Tam, Y. Y., Oskouian, B., & Saba, J. D. (2005). The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. Journal of Biological Chemistry, 280(40), 33697–33700. doi: 10.1074/jbc.C500294200.PubMedCrossRefGoogle Scholar
  13. Baudhuin, L. M., Jiang, Y., Zaslavsky, A., Ishii, I., Chun, J., & Xu, Y. (2004). S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB Journal, 18(2), 341–343.PubMedGoogle Scholar
  14. Ben-David, O., & Futerman, A. H. (2010). The role of the ceramide acyl chain length in neurodegeneration: Involvement of ceramide synthases. Neuromolecular Medicine, 12(4), 341–350. doi: 10.1007/s12017-010-8114-x.PubMedCrossRefGoogle Scholar
  15. Bensemhoun, J., Bombarda, I., Aknin, M., Faure, R., Vacelet, J., & Gaydou, E. M. (2008). Marine bifunctional sphingolipids from the sponge Oceanapia ramsayi. Molecules, 13(4), 772–778.PubMedCrossRefGoogle Scholar
  16. Bertea, M., Rutti, M. F., Othman, A., Marti-Jaun, J., Hersberger, M., von Eckardstein, A., et al. (2010). Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids in Health and Disease, 9, 84. doi: 10.1186/1476-511X-9-84.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Bode, H., Bourquin, F., Suriyanarayanan, S., Wei, Y., Alecu, I., Othman, A., et al. (2015). HSAN1 mutations in serine palmitoyltransferase reveal a close structure-function-phenotype relationship. Human Molecular Genetics,. doi: 10.1093/hmg/ddv611.Google Scholar
  18. Bohler, T., Budde, K., Neumayer, H. H., & Waiser, J. (2005). Novel mediators of FTY720 in human lymphocytes. Transplantation, 79(4), 492–495.PubMedCrossRefGoogle Scholar
  19. Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., et al. (2010). Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. [Review]. Nature Reviews Drug Discovery, 9(11), 883–897. doi: 10.1038/nrd3248.PubMedCrossRefGoogle Scholar
  20. Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., et al. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Journal of Biological Chemistry, 277(24), 21453–21457.PubMedCrossRefGoogle Scholar
  21. Buehrer, B. M., & Bell, R. M. (1992). Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. Journal of Biological Chemistry, 267(5), 3154–3159.PubMedGoogle Scholar
  22. Byrdwell, W. C., & Perry, R. H. (2007). Liquid chromatography with dual parallel mass spectrometry and 31P nuclear magnetic resonance spectroscopy for analysis of sphingomyelin and dihydrosphingomyelin. II. Bovine milk sphingolipids. Journal of Chromatography A, 1146(2), 164–185. doi: 10.1016/j.chroma.2007.01.108.PubMedCrossRefGoogle Scholar
  23. Canals, D., & Hannun, Y. A. (2013). Novel chemotherapeutic drugs in sphingolipid cancer research. Handbook of Experimental Pharmacology, 215, 211–238. doi: 10.1007/978-3-7091-1368-4_12.PubMedCrossRefGoogle Scholar
  24. Chiba, K., Hoshino, Y., Suzuki, C., Masubuchi, Y., Yanagawa, Y., Ohtsuki, M., et al. (1996). FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplantation Proceedings, 28(2), 1056–1059.PubMedGoogle Scholar
  25. Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C. W., Noguchi, K., et al. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proceedings of the National Academy of Sciences of the United States of America, 108(2), 751–756. doi: 10.1073/pnas.1014154108.PubMedCrossRefGoogle Scholar
  26. Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahnstrom, J., Sevvana, M., et al. (2011). Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proceedings of the National Academy of Sciences of the United States of America, 108(23), 9613–9618. doi: 10.1073/pnas.1103187108.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Chueh, S. C., Tian, L., Wang, M., Wang, M. E., Stepkowski, S. M., & Kahan, B. D. (1997). Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720. Transplantation, 64(10), 1407–1414.PubMedCrossRefGoogle Scholar
  28. Chumanevich, A. A., Poudyal, D., Cui, X., Davis, T., Wood, P. A., Smith, C. D., et al. (2010). Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis, 31(10), 1787–1793. doi: 10.1093/carcin/bgq158.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Chun, J., & Brinkmann, V. (2011). A mechanistically novel, first oral therapy for multiple sclerosis: The development of fingolimod (FTY720, Gilenya). [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Discovery Medicine, 12(64), 213–228.PubMedPubMedCentralGoogle Scholar
  30. Chun, J., & Hartung, H. P. (2010). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clinical Neuropharmacology, 33(2), 91–101. doi: 10.1097/WNF.0b013e3181cbf825.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Cingolani, F., Casasampere, M., Sanllehi, P., Casas, J., Bujons, J., & Fabrias, G. (2014). Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. Journal of Lipid Research, 55(8), 1711–1720. doi: 10.1194/jlr.M049759.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Cohen, J. A., & Chun, J. (2011). Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Annals of Neurology, 69(5), 759–777. doi: 10.1002/ana.22426.PubMedCrossRefGoogle Scholar
  33. Cowart, L. A., & Obeid, L. M. (2007). Yeast sphingolipids: Recent developments in understanding biosynthesis, regulation, and function. Biochimica et Biophysica Acta, 1771(3), 421–431. doi: 10.1016/j.bbalip.2006.08.005.PubMedCrossRefGoogle Scholar
  34. de la Monte, S. M., Longato, L., Tong, M., DeNucci, S., & Wands, J. R. (2009). The liver-brain axis of alcohol-mediated neurodegeneration: Role of toxic lipids. International Journal of Environmental Research and Public Health, 6(7), 2055–2075. doi: 10.3390/ijerph6072055.PubMedPubMedCentralCrossRefGoogle Scholar
  35. De Luca, C., & Valacchi, G. (2010). Surface lipids as multifunctional mediators of skin responses to environmental stimuli. Mediators of Inflammation, 2010, 321494. doi: 10.1155/2010/321494.PubMedPubMedCentralGoogle Scholar
  36. Dickson, R. C. (2008). Thematic review series: Sphingolipids. New insights into sphingolipid metabolism and function in budding yeast. Journal of Lipid Research, 49(5), 909–921. doi: 10.1194/jlr.R800003-JLR200.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Dickson, M. A., Carvajal, R. D., Merrill, A. H, Jr., Gonen, M., Cane, L. M., & Schwartz, G. K. (2011). A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clinical Cancer Research, 17(8), 2484–2492. doi: 10.1158/1078-0432.CCR-10-2323.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Duan, J., & Merrill, A. H, Jr. (2015). 1-Deoxysphingolipids encountered exogenously and made de novo: Dangerous mysteries inside an enigma. Journal of Biological Chemistry, 290(25), 15380–15389. doi: 10.1074/jbc.R115.658823.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Dukala, D. E., & Soliven, B. (2016). S1P1 deletion in oligodendroglial lineage cells: Effect on differentiation and myelination. Glia, 64(4), 570–582. doi: 10.1002/glia.22949.PubMedCrossRefGoogle Scholar
  40. Enosawa, S., Suzuki, S., Kakefuda, T., Li, X. K., & Amemiya, H. (1996). Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. Immunopharmacology, 34(2–3), 171–179.CrossRefPubMedGoogle Scholar
  41. Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K., Merrill, A. H, Jr., Murphy, R. C., et al. (2005). A comprehensive classification system for lipids. Journal of Lipid Research, 46(5), 839–861. doi: 10.1194/jlr.E400004-JLR200.PubMedCrossRefGoogle Scholar
  42. Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R., Shimizu, T., et al. (2009). Update of the LIPID MAPS comprehensive classification system for lipids. Journal of Lipid Research, 50(Suppl), S9–S14. doi: 10.1194/jlr.R800095-JLR200.PubMedPubMedCentralGoogle Scholar
  43. Felding-Habermann, B., Igarashi, Y., Fenderson, B. A., Park, L. S., Radin, N. S., Inokuchi, J., et al. (1990). A ceramide analogue inhibits T cell proliferative response through inhibition of glycosphingolipid synthesis and enhancement of N,N-dimethylsphingosine synthesis. Biochemistry, 29(26), 6314–6322.PubMedCrossRefGoogle Scholar
  44. Finley, K. D., Edeen, P. T., Cumming, R. C., Mardahl-Dumesnil, M. D., Taylor, B. J., Rodriguez, M. H., et al. (2003). blue cheese mutations define a novel, conserved gene involved in progressive neural degeneration. Journal of Neuroscience, 23(4), 1254–1264.PubMedPubMedCentralGoogle Scholar
  45. Fleischmann, R. (2012). Novel small-molecular therapeutics for rheumatoid arthritis. Current Opinion in Rheumatology, 24(3), 335–341. doi: 10.1097/BOR.0b013e32835190ef.PubMedCrossRefGoogle Scholar
  46. Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., et al. (2003). Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. Journal of Pharmacology and Experimental Therapeutics, 305(1), 70–77.PubMedCrossRefGoogle Scholar
  47. Fujita, T., Inoue, K., Yamamoto, S., Ikumoto, T., Sasaki, S., Toyama, R., et al. (1994). Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyriocin, (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives. Journal of Antibiotics (Tokyo), 47(2), 216–224.CrossRefGoogle Scholar
  48. Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A., & Chun, J. (2001). Lysophospholipid receptors. Annual Review of Pharmacology and Toxicology, 41, 507–534.PubMedCrossRefGoogle Scholar
  49. Furukawa, A., Kita, K., Toyomoto, M., Fujii, S., Inoue, S., Hayashi, K., et al. (2007). Production of nerve growth factor enhanced in cultured mouse astrocytes by glycerophospholipids, sphingolipids, and their related compounds. Molecular and Cellular Biochemistry, 305(1–2), 27–34. doi: 10.1007/s11010-007-9524-4.PubMedCrossRefGoogle Scholar
  50. Fyrst, H., Herr, D. R., Harris, G. L., & Saba, J. D. (2004). Characterization of free endogenous C14 and C16 sphingoid bases from Drosophila melanogaster. Journal of Lipid Research, 45(1), 54–62. doi: 10.1194/jlr.M300005-JLR200.PubMedCrossRefGoogle Scholar
  51. Fyrst, H., Oskouian, B., Bandhuvula, P., Gong, Y. Q., Byun, H. S., Bittman, R., et al. (2009). Natural sphingadienes inhibit Akt-dependent signaling and prevent intestinal tumorigenesis. Cancer Research, 69(24), 9457–9464. doi: 10.1158/0008-5472.Can-09-2341.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Fyrst, H., & Saba, J. D. (2010). An update on sphingosine-1-phosphate and other sphingolipid mediators. Nature Chemical Biology, 6(7), 489–497. doi: 10.1038/nchembio.392.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Fyrst, H., Zhang, X., Herr, D. R., Byun, H. S., Bittman, R., Phan, V. H., et al. (2008). Identification and characterization by electrospray mass spectrometry of endogenous Drosophila sphingadienes. Journal of Lipid Research, 49(3), 597–606. doi: 10.1194/jlr.M700414-JLR200.PubMedCrossRefGoogle Scholar
  54. Garnier-Amblard, E. C., Mays, S. G., Arrendale, R. F., Baillie, M. T., Bushnev, A. S., Culver, D. G., et al. (2011). Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer. ACS Medicinal Chemistry Letters, 2(6), 438–443. doi: 10.1021/ml2000164.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Ghasemi, R., Dargahi, L., & Ahmadiani, A. (2016). Integrated sphingosine-1 phosphate signaling in the central nervous system: From physiological equilibrium to pathological damage. Pharmacological Research, 104, 156–164. doi: 10.1016/j.phrs.2015.11.006.PubMedCrossRefGoogle Scholar
  56. Gibellini, F., & Smith, T. K. (2010). The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life, 62(6), 414–428. doi: 10.1002/iub.337.PubMedCrossRefGoogle Scholar
  57. Godfrey, J., Jeanguenin, L., Castro, N., Olney, J. J., Dudley, J., Pipkin, J., et al. (2015). Chronic voluntary ethanol consumption induces favorable ceramide profiles in selectively bred alcohol-preferring (P) rats. PLoS ONE, 10(9), e0139012. doi: 10.1371/journal.pone.0139012.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Gomez-Munoz, A., Presa, N., Gomez-Larrauri, A., Rivera, I. G., Trueba, M., & Ordonez, M. (2016). Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate. Progress in Lipid Research, 61, 51–62. doi: 10.1016/j.plipres.2015.09.002.PubMedCrossRefGoogle Scholar
  59. Groves, A., Kihara, Y., & Chun, J. (2013). Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. Journal of the Neurological Sciences, 328(1–2), 9–18. doi: 10.1016/j.jns.2013.02.011.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Gulbins, E., Walter, S., Becker, K. A., Halmer, R., Liu, Y., Reichel, M., et al. (2015). A central role for the acid sphingomyelinase/ceramide system in neurogenesis and major depression. Journal of Neurochemistry, 134(2), 183–192. doi: 10.1111/jnc.13145.PubMedCrossRefGoogle Scholar
  61. Han, G., Gupta, S. D., Gable, K., Niranjanakumari, S., Moitra, P., Eichler, F., et al. (2009). Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities. Proceedings of the National Academy of Sciences of the United States of America, 106(20), 8186–8191. doi: 10.1073/pnas.0811269106.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Hanson, M. A., Roth, C. B., Jo, E., Griffith, M. T., Scott, F. L., Reinhart, G., et al. (2012). Crystal structure of a lipid G protein-coupled receptor. Science, 335(6070), 851–855. doi: 10.1126/science.1215904.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Hebbar, S., Sahoo, I., Matysik, A., Argudo Garcia, I., Osborne, K. A., Papan, C., et al. (2015). Ceramides and stress signalling intersect with autophagic defects in neurodegenerative Drosophila blue cheese (bchs) mutants. Scientific Reports, 5, 15926. doi: 10.1038/srep15926.PubMedPubMedCentralCrossRefGoogle Scholar
  64. Hecht, J. H., Weiner, J. A., Post, S. R., & Chun, J. (1996). Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. Journal of Cell Biology, 135(4), 1071–1083.PubMedCrossRefGoogle Scholar
  65. Herr, D. R., & Chun, J. (2007). Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Current Drug Targets, 8(1), 155–167.PubMedCrossRefGoogle Scholar
  66. Herr, D. R., Grillet, N., Schwander, M., Rivera, R., Muller, U., & Chun, J. (2007). Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. Journal of Neuroscience, 27(6), 1474–1478. doi: 10.1523/JNEUROSCI.4245-06.2007.PubMedCrossRefGoogle Scholar
  67. Herr, D. R., Lee, C. W., Wang, W., Ware, A., Rivera, R., & Chun, J. (2013). Sphingosine 1-phosphate receptors are essential mediators of eyelid closure during embryonic development. Journal of Biological Chemistry, 288(41), 29882–29889. doi: 10.1074/jbc.M113.510099.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Herr, D. R., Reolo, M. J., Peh, Y. X., Wang, W., Lee, C. W., Rivera, R., et al. (2016). Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: Implications for otoprotective therapy. Scientific Reports, 6, 24541. doi: 10.1038/srep24541.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Heusler, K., & Pletscher, A. (2001). The controversial early history of cyclosporin. Swiss Medical Weekly, 131(21–22), 299–302. doi:2001/21/smw-09702. Google Scholar
  70. Hoeferlin, L. A., Wijesinghe, D. S., & Chalfant, C. E. (2013). The role of ceramide-1-phosphate in biological functions. Handbook of Experimental Pharmacology, 215, 153–166. doi: 10.1007/978-3-7091-1368-4_8.PubMedCrossRefGoogle Scholar
  71. Hopson, K. P., Truelove, J., Chun, J., Wang, Y., & Waeber, C. (2011). S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells. American Journal of Physiology. Cell Physiology, 300(4), C919–C926. doi: 10.1152/ajpcell.00350.2010.PubMedCrossRefGoogle Scholar
  72. Hornemann, T., Penno, A., Rutti, M. F., Ernst, D., Kivrak-Pfiffner, F., Rohrer, L., et al. (2009). The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. Journal of Biological Chemistry, 284(39), 26322–26330. doi: 10.1074/jbc.M109.023192.PubMedPubMedCentralCrossRefGoogle Scholar
  73. Hornemann, T., Wei, Y., & von Eckardstein, A. (2007). Is the mammalian serine palmitoyltransferase a high-molecular-mass complex? Biochemical Journal, 405(1), 157–164. doi: 10.1042/BJ20070025.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Hoshino, Y., Suzuki, C., Ohtsuki, M., Masubuchi, Y., Amano, Y., & Chiba, K. (1996). FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplantation Proceedings, 28(2), 1060–1061.PubMedGoogle Scholar
  75. Hulette, C. M., Earl, N. L., Anthony, D. C., & Crain, B. J. (1992). Adult onset Niemann-Pick disease type C presenting with dementia and absent organomegaly. Clinical Neuropathology, 11(6), 293–297.PubMedGoogle Scholar
  76. Igarashi, Y., Kitamura, K., Toyokuni, T., Dean, B., Fenderson, B., Ogawass, T., et al. (1990). A specific enhancing effect of N,N-dimethylsphingosine on epidermal growth factor receptor autophosphorylation. Demonstration of its endogenous occurrence (and the virtual absence of unsubstituted sphingosine) in human epidermoid carcinoma A431 cells. Journal of Biological Chemistry, 265(10), 5385–5389.PubMedGoogle Scholar
  77. Ikeda, K., & Taguchi, R. (2010). Highly sensitive localization analysis of gangliosides and sulfatides including structural isomers in mouse cerebellum sections by combination of laser microdissection and hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry with theoretically expanded multiple reaction monitoring. Rapid Communications in Mass Spectrometry, 24(20), 2957–2965. doi: 10.1002/rcm.4716.PubMedCrossRefGoogle Scholar
  78. Imai, H., Ohnishi, M., Hotsubo, K., Kojima, M., & Ito, S. (1997). Sphingoid base composition of cerebrosides from plant leaves. Bioscience, Biotechnology, and Biochemistry, 61(2), 351–353.CrossRefGoogle Scholar
  79. Inamine, M., Suzui, M., Morioka, T., Kinjo, T., Kaneshiro, T., Sugishita, T., et al. (2005). Inhibitory effect of dietary monoglucosylceramide 1-O-beta-glucosyl-N-2′-hydroxyarachidoyl-4,8-sphingadienine on two different categories of colon preneoplastic lesions induced by 1,2-dimethylhydrazine in F344 rats. Cancer Science, 96(12), 876–881. doi: 10.1111/j.1349-7006.2005.00127.x.PubMedCrossRefGoogle Scholar
  80. Ishii, I., Friedman, B., Ye, X., Kawamura, S., McGiffert, C., Contos, J. J., et al. (2001). Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. Journal of Biological Chemistry, 276(36), 33697–33704. Epub 32001 Jul 33696.PubMedCrossRefGoogle Scholar
  81. Ishii, I., Ye, X., Friedman, B., Kawamura, S., Contos, J. J., Kingsbury, M. A., et al. (2002). Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. Journal of Biological Chemistry, 277(28), 25152–25159. Epub 22002 May 25152.PubMedCrossRefGoogle Scholar
  82. Jaillard, C., Harrison, S., Stankoff, B., Aigrot, M. S., Calver, A. R., Duddy, G., et al. (2005). Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. Journal of Neuroscience, 25(6), 1459–1469. doi: 10.1523/JNEUROSCI.4645-04.2005.PubMedCrossRefGoogle Scholar
  83. Jana, A., Hogan, E. L., & Pahan, K. (2009). Ceramide and neurodegeneration: Susceptibility of neurons and oligodendrocytes to cell damage and death. Journal of the Neurological Sciences, 278(1–2), 5–15. doi: 10.1016/j.jns.2008.12.010.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Kappos, L., Antel, J., Comi, G., Montalban, X., O’Connor, P., Polman, C. H., et al. (2006). Oral fingolimod (FTY720) for relapsing multiple sclerosis [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. New England Journal of Medicine, 355(11), 1124–1140. doi: 10.1056/NEJMoa052643.PubMedCrossRefGoogle Scholar
  85. Kawaguchi, T., Hoshino, Y., Rahman, F., Amano, Y., Higashi, H., Kataoka, H., et al. (1996). FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplantation Proceedings, 28(2), 1062–1063.PubMedGoogle Scholar
  86. Kawamori, T., Kaneshiro, T., Okumura, M., Maalouf, S., Uflacker, A., Bielawski, J., et al. (2009). Role for sphingosine kinase 1 in colon carcinogenesis. FASEB Journal, 23(2), 405–414. doi: 10.1096/fj.08-117572.PubMedPubMedCentralCrossRefGoogle Scholar
  87. Kawamori, T., Osta, W., Johnson, K. R., Pettus, B. J., Bielawski, J., Tanaka, T., et al. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB Journal, 20(2), 386–388. doi: 10.1096/fj.05-4331fje.PubMedGoogle Scholar
  88. Keller, C. D., Rivera Gil, P., Tolle, M., van der Giet, M., Chun, J., Radeke, H. H., et al. (2007). Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. American Journal of Pathology, 170(1), 281–292.PubMedPubMedCentralCrossRefGoogle Scholar
  89. Keranen, A. (1976). Fatty acids and long-chain bases of gangliosides of human gastrointestinal mucosa. Chemistry and Physics of Lipids, 17(1), 14–21.PubMedCrossRefGoogle Scholar
  90. Kihara, Y., Maceyka, M., Spiegel, S., & Chun, J. (2014). Lysophospholipid receptor nomenclature review: IUPHAR Review 8. British Journal of Pharmacology, 171(15), 3575–3594. doi: 10.1111/bph.12678.PubMedPubMedCentralCrossRefGoogle Scholar
  91. Kihara, Y., Mizuno, H., & Chun, J. (2015). Lysophospholipid receptors in drug discovery. Experimental Cell Research, 333(2), 171–177. doi: 10.1016/j.yexcr.2014.11.020.PubMedCrossRefGoogle Scholar
  92. Kim, G. S., Yang, L., Zhang, G., Zhao, H., Selim, M., McCullough, L. D., et al. (2015). Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nature Communications, 6, 7893. doi: 10.1038/ncomms8893.PubMedPubMedCentralCrossRefGoogle Scholar
  93. Kitatani, K., Idkowiak-Baldys, J., & Hannun, Y. A. (2008). The sphingolipid salvage pathway in ceramide metabolism and signaling. Cellular Signalling, 20(6), 1010–1018. doi: 10.1016/j.cellsig.2007.12.006.PubMedCrossRefGoogle Scholar
  94. Kluepfel, D., Bagli, J., Baker, H., Charest, M. P., & Kudelski, A. (1972). Myriocin, a new antifungal antibiotic from Myriococcum albomyces. Journal of Antibiotics (Tokyo), 25(2), 109–115.CrossRefGoogle Scholar
  95. Kornhuber, J., Muller, C. P., Becker, K. A., Reichel, M., & Gulbins, E. (2014). The ceramide system as a novel antidepressant target. Trends in Pharmacological Sciences, 35(6), 293–304. doi: 10.1016/j.tips.2014.04.003.PubMedCrossRefGoogle Scholar
  96. Kumar, A., Pandurangan, A. K., Lu, F., Fyrst, H., Zhang, M., Byun, H. S., et al. (2012). Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3beta pathway in colon cancer. Carcinogenesis, 33(9), 1726–1735. doi: 10.1093/carcin/bgs174.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013). Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nature Reviews Drug Discovery, 12(9), 688–702. doi: 10.1038/nrd4099.PubMedPubMedCentralCrossRefGoogle Scholar
  98. Kwon, H. C., Lee, K. C., Cho, O. R., Jung, I. Y., Cho, S. Y., Kim, S. Y., et al. (2003). Sphingolipids from Bombycis Corpus 101A and their neurotrophic effects. Journal of Natural Products, 66(4), 466–469. doi: 10.1021/np0204491.PubMedCrossRefGoogle Scholar
  99. Lamour, N. F., & Chalfant, C. E. (2005). Ceramide-1-phosphate: The “missing” link in eicosanoid biosynthesis and inflammation. Molecular Interventions, 5(6), 358–367. doi: 10.1124/mi.5.6.8.PubMedCrossRefGoogle Scholar
  100. Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., et al. (2010). STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature Medicine, 16(12), 1421–1428. doi: 10.1038/nm.2250.PubMedPubMedCentralCrossRefGoogle Scholar
  101. Lee, T. C., Ou, M. C., Shinozaki, K., Malone, B., & Snyder, F. (1996). Biosynthesis of N-acetylsphingosine by platelet-activating factor: Sphingosine CoA-independent transacetylase in HL-60 cells. Journal of Biological Chemistry, 271(1), 209–217.PubMedCrossRefGoogle Scholar
  102. Lee, M. J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., et al. (1999). Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell, 99(3), 301–312.PubMedCrossRefGoogle Scholar
  103. Lee, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., et al. (1998). Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science, 279(5356), 1552–1555.PubMedCrossRefGoogle Scholar
  104. Levy, M., & Futerman, A. H. (2010). Mammalian ceramide synthases. IUBMB Life, 62(5), 347–356. doi: 10.1002/iub.319.PubMedPubMedCentralGoogle Scholar
  105. Liu, J., Zhang, C., Tao, W., & Liu, M. (2013). Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. International Journal of Neuroscience, 123(3), 163–169. doi: 10.3109/00207454.2012.749255.PubMedCrossRefGoogle Scholar
  106. Lynch, D. V., & Dunn, T. M. (2004). An introduction to plant sphingolipids and a review of recent advances in understanding their metabolism and function. New Phytologist, 161(3), 677–702. doi: 10.1111/j.1469-8137.2004.00992.x.CrossRefGoogle Scholar
  107. Macauley, S. L., Sidman, R. L., Schuchman, E. H., Taksir, T., & Stewart, G. R. (2008). Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration. Experimental Neurology, 214(2), 181–192. doi: 10.1016/j.expneurol.2008.07.026.PubMedCrossRefGoogle Scholar
  108. MacLennan, A. J., Carney, P. R., Zhu, W. J., Chaves, A. H., Garcia, J., Grimes, J. R., et al. (2001). An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. European Journal of Neuroscience, 14(2), 203–209.PubMedCrossRefGoogle Scholar
  109. Malchinkhuu, E., Sato, K., Muraki, T., Ishikawa, K., Kuwabara, A., & Okajima, F. (2003). Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function. Biochemical Journal, 370(Pt 3), 817–827.PubMedPubMedCentralCrossRefGoogle Scholar
  110. Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., et al. (2002). Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science, 296(5566), 346–349.PubMedCrossRefGoogle Scholar
  111. Martinez, T. N., Chen, X., Bandyopadhyay, S., Merrill, A. H., & Tansey, M. G. (2012). Ceramide sphingolipid signaling mediates tumor necrosis factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Molecular Neurodegeneration, 7, 45. doi: 10.1186/1750-1326-7-45.PubMedPubMedCentralCrossRefGoogle Scholar
  112. Masubuchi, Y., Kawaguchi, T., Ohtsuki, M., Suzuki, C., Amano, Y., Hoshino, Y., et al. (1996). FTY720, a novel immunosuppressant, possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats. Transplantation Proceedings, 28(2), 1064–1065.PubMedGoogle Scholar
  113. Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., et al. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 427(6972), 355–360.PubMedCrossRefGoogle Scholar
  114. Matsuoka, Y., Nagahara, Y., Ikekita, M., & Shinomiya, T. (2003). A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. British Journal of Pharmacology, 138(7), 1303–1312. doi: 10.1038/sj.bjp.0705182.PubMedPubMedCentralCrossRefGoogle Scholar
  115. McNaughton, M., Pitman, M., Pitson, S. M., Pyne, N. J., & Pyne, S. (2016). Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget, 7(13), 16663–16675. doi: 10.18632/oncotarget.7693.PubMedPubMedCentralGoogle Scholar
  116. Means, C. K., Miyamoto, S., Chun, J., & Brown, J. H. (2008). S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. Journal of Biological Chemistry, 283(18), 11954–11963. doi: 10.1074/jbc.M707422200.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Means, C. K., Xiao, C. Y., Li, Z., Zhang, T., Omens, J. H., Ishii, I., et al. (2007). Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. American Journal of Physiology: Heart and Circulatory Physiology, 292(6), H2944–H2951. doi: 10.1152/ajpheart.01331.2006.PubMedGoogle Scholar
  118. Merrill, A. H, Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chemical Reviews, 111(10), 6387–6422. doi: 10.1021/cr2002917.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Merrill, A. H, Jr., Stokes, T. H., Momin, A., Park, H., Portz, B. J., Kelly, S., et al. (2009). Sphingolipidomics: A valuable tool for understanding the roles of sphingolipids in biology and disease. Journal of Lipid Research, 50(Suppl), S97–S102. doi: 10.1194/jlr.R800073-JLR200.PubMedPubMedCentralGoogle Scholar
  120. Merrill, A. H, Jr., Sullards, M. C., Allegood, J. C., Kelly, S., & Wang, E. (2005). Sphingolipidomics: High-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods, 36(2), 207–224. doi: 10.1016/j.ymeth.2005.01.009.PubMedCrossRefGoogle Scholar
  121. Merrill, A. H, Jr., Wang, E., Mullins, R. E., Jamison, W. C., Nimkar, S., & Liotta, D. C. (1988). Quantitation of free sphingosine in liver by high-performance liquid chromatography. Analytical Biochemistry, 171(2), 373–381.PubMedCrossRefGoogle Scholar
  122. Mielke, M. M., & Haughey, N. J. (2012). Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer’s disease? Clinical Lipidology, 7(5), 525–536. doi: 10.2217/clp.12.59.PubMedPubMedCentralCrossRefGoogle Scholar
  123. Missmer, S. A., Suarez, L., Felkner, M., Wang, E., Merrill, A. H, Jr., Rothman, K. J., et al. (2006). Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. Environmental Health Perspectives, 114(2), 237–241.PubMedCrossRefGoogle Scholar
  124. Mitsusada, M., Suzuki, S., Kobayashi, E., Enosawa, S., Kakefuda, T., & Miyata, M. (1997). Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation. Transplantation International, 10(5), 343–349.Google Scholar
  125. Miyake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T., & Kawasaki, T. (1995). Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochemical and Biophysical Research Communications, 211(2), 396–403.PubMedCrossRefGoogle Scholar
  126. Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S., & Proia, R. L. (2005). Essential role for sphingosine kinases in neural and vascular development. Molecular and Cellular Biology, 25(24), 11113–11121. doi: 10.1128/MCB.25.24.11113-11121.2005.PubMedPubMedCentralCrossRefGoogle Scholar
  127. Mizushina, Y., Hanashima, L., Yamaguchi, T., Takemura, M., Sugawara, F., Saneyoshi, M., et al. (1998). A mushroom fruiting body-inducing substance inhibits activities of replicative DNA polymerases. Biochemical and Biophysical Research Communications, 249(1), 17–22. doi: 10.1006/bbrc.1998.9091.PubMedCrossRefGoogle Scholar
  128. Moon, E., Han, J. E., Jeon, S., Ryu, J. H., Choi, J. W., & Chun, J. (2015). Exogenous S1P exposure potentiates ischemic stroke damage that is reduced possibly by inhibiting S1P receptor signaling. Mediators of Inflammation, 2015, 492659. doi: 10.1155/2015/492659.PubMedPubMedCentralCrossRefGoogle Scholar
  129. Motta, S., Monti, M., Sesana, S., Mellesi, L., Ghidoni, R., & Caputo, R. (1994). Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Archives of Dermatology, 130(4), 452–456.PubMedCrossRefGoogle Scholar
  130. Mutoh, T., Rivera, R., & Chun, J. (2012). Insights into the pharmacological relevance of lysophospholipid receptors. British Journal of Pharmacology, 165(4), 829–844. doi: 10.1111/j.1476-5381.2011.01622.x.PubMedPubMedCentralCrossRefGoogle Scholar
  131. Nagle, D. G., McClatchey, W. C., & Gerwick, W. H. (1992). New glycosphingolipids from the marine sponge Halichondria panicea. Journal of Natural Products, 55(7), 1013–1017.PubMedCrossRefGoogle Scholar
  132. Napoli, K. L. (2000). The FTY720 story. Therapeutic Drug Monitoring, 22(1), 47–51.PubMedCrossRefGoogle Scholar
  133. Narayanaswamy, P., Shinde, S., Sulc, R., Kraut, R., Staples, G., Thiam, C. H., et al. (2014). Lipidomic “deep profiling”: An enhanced workflow to reveal new molecular species of signaling lipids. Analytical Chemistry, 86(6), 3043–3047. doi: 10.1021/ac4039652.PubMedCrossRefGoogle Scholar
  134. Nicholas, G. M., & Molinski, T. F. (2000). Enantiodivergent biosynthesis of the dimeric sphingolipid oceanapiside from the marine sponge Oceanapia phillipensis. Determination of remote stereochemistry. Journal of the American Chemical Society, 122(17), 4011–4019. doi: 10.1021/ja994215o.CrossRefGoogle Scholar
  135. Noda, N., Tanaka, R., Miyahara, K., & Kawasaki, T. (1993). Isolation and characterization of a novel type of glycosphingolipid from Neanthes diversicolor. Biochimica et Biophysica Acta, 1169(1), 30–38.PubMedCrossRefGoogle Scholar
  136. Nofer, J. R., van der Giet, M., Tolle, M., Wolinska, I., von Wnuck Lipinski, K., Baba, H. A., et al. (2004). HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. Journal of Clinical Investigation, 113(4), 569–581.PubMedPubMedCentralCrossRefGoogle Scholar
  137. Novotny, J., Hrabalek, A., & Vavrova, K. (2010). Synthesis and structure-activity relationships of skin ceramides. Current Medicinal Chemistry, 17(21), 2301–2324.PubMedCrossRefGoogle Scholar
  138. Nyberg, L., Nilsson, A., Lundgren, P., & Duan, R. D. (1997). Localization and capacity of sphingomyelin digestion in the rat intestinal tract. Journal of Nutritional Biochemistry, 8(3), 112–118. doi: 10.1016/S0955-2863(97)00010-7.CrossRefGoogle Scholar
  139. Obenberger, J., Seidl, Z., Pavlu, H., & Elleder, M. (1999). MRI in an unusually protracted neuronopathic variant of acid sphingomyelinase deficiency. Neuroradiology, 41(3), 182–184.PubMedCrossRefGoogle Scholar
  140. O’Brien, J. S., & Sampson, E. L. (1965). Lipid composition of the normal human brain: Gray matter, white matter, and myelin. Journal of Lipid Research, 6(4), 537–544.PubMedGoogle Scholar
  141. Ohlsson, L., Hertervig, E., Jonsson, B. A., Duan, R. D., Nyberg, L., Svernlov, R., et al. (2010). Sphingolipids in human ileostomy content after meals containing milk sphingomyelin. American Journal of Clinical Nutrition, 91(3), 672–678. doi: 10.3945/ajcn.2009.28311.CrossRefPubMedGoogle Scholar
  142. Okuyama, E., & Yamazaki, M. (1983). The principles of Tetragonia tetragonoides having anti-ulcerogenic activity. II. Isolation and structure of cerebrosides. Chemical and Pharmaceutical Bulletin, 31(7), 2209–2219.PubMedCrossRefGoogle Scholar
  143. Olsen, I., & Jantzen, E. (2001). Sphingolipids in bacteria and fungi. Anaerobe, 7(2), 103–112. doi: 10.1006/anae.2001.0376.CrossRefGoogle Scholar
  144. Ong, W. Y., Herr, D. R., Farooqui, T., Ling, E. A., & Farooqui, A. A. (2015). Role of sphingomyelinases in neurological disorders. Expert Opinion on Therapeutic Targets, 19(12), 1725–1742. doi: 10.1517/14728222.2015.1071794.PubMedCrossRefGoogle Scholar
  145. Oo, M. L., Thangada, S., Wu, M. T., Liu, C. H., Macdonald, T. L., Lynch, K. R., et al. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Journal of Biological Chemistry, 282(12), 9082–9089. doi: 10.1074/jbc.M610318200.PubMedCrossRefGoogle Scholar
  146. Othman, A., Bianchi, R., Alecu, I., Wei, Y., Porretta-Serapiglia, C., Lombardi, R., et al. (2015). Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats. Diabetes, 64(3), 1035–1045. doi: 10.2337/db14-1325.PubMedCrossRefGoogle Scholar
  147. Panganamala, R. V., Geer, J. C., & Cornwell, D. G. (1969). Long-chain bases in the sphingolipids of atherosclerotic human aorta. Journal of Lipid Research, 10(4), 445–455.PubMedGoogle Scholar
  148. Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., Xu, Y., et al. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 316(5822), 295–298.PubMedCrossRefGoogle Scholar
  149. Patmanathan, S. N., Johnson, S. P., Lai, S. L., Panja Bernam, S., Lopes, V., Wei, W., et al. (2016). Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. Scientific Reports, 6, 25650. doi: 10.1038/srep25650.PubMedPubMedCentralCrossRefGoogle Scholar
  150. Patmanathan, S. N., Yap, L. F., Murray, P. G., & Paterson, I. C. (2015). The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod. Journal of Cellular and Molecular Medicine, 19(10), 2329–2340. doi: 10.1111/jcmm.12635.PubMedPubMedCentralCrossRefGoogle Scholar
  151. Pebay, A., Toutant, M., Premont, J., Calvo, C. F., Venance, L., Cordier, J., et al. (2001). Sphingosine-1-phosphate induces proliferation of astrocytes: Regulation by intracellular signalling cascades. European Journal of Neuroscience, 13(12), 2067–2076.CrossRefGoogle Scholar
  152. Penno, A., Reilly, M. M., Houlden, H., Laura, M., Rentsch, K., Niederkofler, V., et al. (2010). Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. Journal of Biological Chemistry, 285(15), 11178–11187. doi: 10.1074/jbc.M109.092973.PubMedPubMedCentralCrossRefGoogle Scholar
  153. Pruett, S. T., Bushnev, A., Hagedorn, K., Adiga, M., Haynes, C. A., Sullards, M. C., et al. (2008). Biodiversity of sphingoid bases (“sphingosines”) and related amino alcohols. Journal of Lipid Research, 49(8), 1621–1639. doi: 10.1194/jlr.R800012-JLR200.PubMedPubMedCentralCrossRefGoogle Scholar
  154. Pulkoski-Gross, M. J., Donaldson, J. C., & Obeid, L. M. (2015). Sphingosine-1-phosphate metabolism: A structural perspective. Critical Reviews in Biochemistry and Molecular Biology, 50(4), 298–313. doi: 10.3109/10409238.2015.1039115.PubMedCrossRefGoogle Scholar
  155. Pyne, S., & Pyne, N. J. (2000). Sphingosine 1-phosphate signalling in mammalian cells. Biochemical Journal, 349, 385–402.PubMedPubMedCentralCrossRefGoogle Scholar
  156. Pyne, S., & Pyne, N. J. (2002). Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. Biochimica et Biophysica Acta, 1582(1–3), 121–131.PubMedCrossRefGoogle Scholar
  157. Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., et al. (2010). Lipidomics reveals a remarkable diversity of lipids in human plasma. Journal of Lipid Research, 51(11), 3299–3305. doi: 10.1194/jlr.M009449.PubMedPubMedCentralCrossRefGoogle Scholar
  158. Rao, T. S., Lariosa-Willingham, K. D., Lin, F. F., Palfreyman, E. L., Yu, N., Chun, J., et al. (2003). Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Research, 990(1–2), 182–194.PubMedCrossRefGoogle Scholar
  159. Renkonen, O., & Hirvisalo, E. L. (1969). Structure of plasma sphingadienine. Journal of Lipid Research, 10(6), 687–693.PubMedGoogle Scholar
  160. Reynolds, C. P., Maurer, B. J., & Kolesnick, R. N. (2004). Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Letters, 206(2), 169–180. doi: 10.1016/j.canlet.2003.08.034.PubMedCrossRefGoogle Scholar
  161. Riley, R. T., An, N. H., Showker, J. L., Yoo, H. S., Norred, W. P., Chamberlain, W. J., et al. (1993). Alteration of tissue and serum sphinganine to sphingosine ratio: An early biomarker of exposure to fumonisin-containing feeds in pigs. Toxicology and Applied Pharmacology, 118(1), 105–112.PubMedCrossRefGoogle Scholar
  162. Row, L. C., Ho, J. C., & Chen, C. M. (2007). Cerebrosides and tocopherol trimers from the seeds of Euryale ferox. Journal of Natural Products, 70(7), 1214–1217. doi: 10.1021/np070095j.PubMedCrossRefGoogle Scholar
  163. Rozema, E., Binder, M., Bulusu, M., Bochkov, V., Krupitza, G., & Kopp, B. (2012a). Effects on inflammatory responses by the sphingoid base 4,8-sphingadienine. International Journal of Molecular Medicine, 30(3), 703–707. doi: 10.3892/ijmm.2012.1035.PubMedGoogle Scholar
  164. Rozema, E., Popescu, R., Sonderegger, H., Huck, C. W., Winkler, J., Krupitza, G., et al. (2012b). Characterization of glucocerebrosides and the active metabolite 4,8-sphingadienine from Arisaema amurense and Pinellia ternata by NMR and CD spectroscopy and ESI-MS/CID-MS. Journal of Agricultural and Food Chemistry, 60(29), 7204–7210. doi: 10.1021/jf302085u.PubMedCrossRefGoogle Scholar
  165. Russo, S. B., Tidhar, R., Futerman, A. H., & Cowart, L. A. (2013). Myristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties. Journal of Biological Chemistry, 288(19), 13397–13409. doi: 10.1074/jbc.M112.428185.PubMedPubMedCentralCrossRefGoogle Scholar
  166. Saba, J. D., Nara, F., Bielawska, A., Garrett, S., & Hannun, Y. A. (1997). The BST1 gene of Saccharomyces cerevisiae is the sphingosine-1-phosphate lyase. Journal of Biological Chemistry, 272(42), 26087–26090.PubMedCrossRefGoogle Scholar
  167. Sadler, T. W., Merrill, A. H., Stevens, V. L., Sullards, M. C., Wang, E., & Wang, P. (2002). Prevention of fumonisin B1-induced neural tube defects by folic acid. Teratology, 66(4), 169–176. doi: 10.1002/tera.10089.PubMedCrossRefGoogle Scholar
  168. Saito, M., Chakraborty, G., Hegde, M., Ohsie, J., Paik, S. M., Vadasz, C., et al. (2010). Involvement of ceramide in ethanol-induced apoptotic neurodegeneration in the neonatal mouse brain. Journal of Neurochemistry, 115(1), 168–177. doi: 10.1111/j.1471-4159.2010.06913.x.PubMedPubMedCentralCrossRefGoogle Scholar
  169. Salcedo, M., Cuevas, C., Alonso, J. L., Otero, G., Faircloth, G., Fernandez-Sousa, J. M., et al. (2007). The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis, 12(2), 395–409. doi: 10.1007/s10495-006-0573-z.PubMedCrossRefGoogle Scholar
  170. Sanchez, A. M., Malagarie-Cazenave, S., Olea, N., Vara, D., Cuevas, C., & Diaz-Laviada, I. (2008). Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. European Journal of Pharmacology, 584(2–3), 237–245. doi: 10.1016/j.ejphar.2008.02.011.PubMedCrossRefGoogle Scholar
  171. Santos-Cortez, R. L., Faridi, R., Rehman, A. U., Lee, K., Ansar, M., Wang, X., et al. (2016). Autosomal-recessive hearing impairment due to rare missense variants within S1PR2. American Journal of Human Genetics,. doi: 10.1016/j.ajhg.2015.12.004.PubMedPubMedCentralGoogle Scholar
  172. Sato, K., Ishikawa, K., Ui, M., & Okajima, F. (1999). Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells. Brain Research Molecular Brain Research, 74(1–2), 182–189.PubMedCrossRefGoogle Scholar
  173. Schroeder, J. J., Crane, H. M., Xia, J., Liotta, D. C., & Merrill, A. H, Jr. (1994). Disruption of sphingolipid metabolism and stimulation of DNA synthesis by fumonisin B1. A molecular mechanism for carcinogenesis associated with Fusarium moniliforme. Journal of Biological Chemistry, 269(5), 3475–3481.PubMedGoogle Scholar
  174. Schwab, S. R., & Cyster, J. G. (2007). Finding a way out: Lymphocyte egress from lymphoid organs. Nature Immunology, 8(12), 1295–1301.PubMedCrossRefGoogle Scholar
  175. Schwartz, G. K., Ward, D., Saltz, L., Casper, E. S., Spiess, T., Mullen, E., et al. (1997). A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clinical Cancer Research, 3(4), 537–543.PubMedGoogle Scholar
  176. Shibuya, H., Kawashima, K., Sakagami, M., Kawanishi, H., Shimomura, M., Ohashi, K., et al. (1990). Sphingolipids and glycerolipids. I. Chemical structures and ionophoretic activities of soya-cerebrosides I and II from soybean. Chemical & Pharmaceutical Bulletin, 38(11), 2933–2938.CrossRefGoogle Scholar
  177. Shui, G., Stebbins, J. W., Lam, B. D., Cheong, W. F., Lam, S. M., Gregoire, F., et al. (2011). Comparative plasma lipidome between human and cynomolgus monkey: Are plasma polar lipids good biomarkers for diabetic monkeys? PLoS ONE, 6(5), e19731. doi: 10.1371/journal.pone.0019731.PubMedPubMedCentralCrossRefGoogle Scholar
  178. Slotte, J. P. (2016). The importance of hydrogen bonding in sphingomyelin’s membrane interactions with co-lipids. Biochimica et Biophysica Acta, 1858(2), 304–310. doi: 10.1016/j.bbamem.2015.12.008.PubMedCrossRefGoogle Scholar
  179. Sorensen, S. D., Nicole, O., Peavy, R. D., Montoya, L. M., Lee, C. J., Murphy, T. J., et al. (2003). Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Molecular Pharmacology, 64(5), 1199–1209. doi: 10.1124/mol.64.5.1199.PubMedCrossRefGoogle Scholar
  180. Spohr, T. C., Dezonne, R. S., Nones, J., Dos Santos Souza, C., Einicker-Lamas, M., Gomes, F. C., et al. (2012). Sphingosine 1-phosphate-primed astrocytes enhance differentiation of neuronal progenitor cells. Journal of Neuroscience Research, 90(10), 1892–1902. doi: 10.1002/jnr.23076.PubMedCrossRefGoogle Scholar
  181. Stahlberg, S., Skolova, B., Madhu, P. K., Vogel, A., Vavrova, K., & Huster, D. (2015). Probing the role of the ceramide acyl chain length and sphingosine unsaturation in model skin barrier lipid mixtures by (2)H solid-state NMR spectroscopy. Langmuir, 31(17), 4906–4915. doi: 10.1021/acs.langmuir.5b00751.PubMedCrossRefGoogle Scholar
  182. St-Jacques, M. (1973). Elucidation of structure and stereochemistry of myriocin. A novel antifungal antibiotic. Journal of Organic Chemistry, 38(7), 1253–1260.PubMedCrossRefGoogle Scholar
  183. Stockmann-Juvala, H., & Savolainen, K. (2008). A review of the toxic effects and mechanisms of action of fumonisin B1. Human and Experimental Toxicology, 27(11), 799–809. doi: 10.1177/0960327108099525.PubMedCrossRefGoogle Scholar
  184. Struckhoff, A. P., Bittman, R., Burow, M. E., Clejan, S., Elliott, S., Hammond, T., et al. (2004). Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. Journal of Pharmacology and Experimental Therapeutics, 309(2), 523–532. doi: 10.1124/jpet.103.062760.PubMedCrossRefGoogle Scholar
  185. Sugawara, T., Kinoshita, M., Ohnishi, M., Nagata, J., & Saito, M. (2003). Digestion of maize sphingolipids in rats and uptake of sphingadienine by Caco-2 cells. Journal of Nutrition, 133(9), 2777–2782.PubMedGoogle Scholar
  186. Sugawara, T., Zaima, N., Yamamoto, A., Sakai, S., Noguchi, R., & Hirata, T. (2006). Isolation of sphingoid bases of sea cucumber cerebrosides and their cytotoxicity against human colon cancer cells. Bioscience, Biotechnology, and Biochemistry, 70(12), 2906–2912. doi: 10.1271/bbb.60318.PubMedCrossRefGoogle Scholar
  187. Sullards, M. C., Lynch, D. V., Merrill, A. H, Jr., & Adams, J. (2000). Structure determination of soybean and wheat glucosylceramides by tandem mass spectrometry. Journal of Mass Spectrometry, 35(3), 347–353. doi: 10.1002/(SICI)1096-9888(200003)35:3<347:AID-JMS941>3.0.CO;2-3.PubMedCrossRefGoogle Scholar
  188. Suzuki, S., Enosawa, S., Kakefuda, T., Shinomiya, T., Amari, M., Naoe, S., et al. (1996). A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation, 61(2), 200–205.PubMedCrossRefGoogle Scholar
  189. Symolon, H., Bushnev, A., Peng, Q., Ramaraju, H., Mays, S. G., Allegood, J. C., et al. (2011). Enigmol: A novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer. Molecular Cancer Therapeutics, 10(4), 648–657. doi: 10.1158/1535-7163.MCT-10-0754.PubMedCrossRefGoogle Scholar
  190. Symolon, H., Schmelz, E. M., Dillehay, D. L., & Merrill, A. H, Jr. (2004). Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. Journal of Nutrition, 134(5), 1157–1161.PubMedGoogle Scholar
  191. Szepanowski, F., Derksen, A., Steiner, I., Meyer Zu Horste, G., Daldrup, T., Hartung, H. P., et al. (2016). Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. Journal of Neuroinflammation, 13(1), 143. doi: 10.1186/s12974-016-0612-9.PubMedPubMedCentralCrossRefGoogle Scholar
  192. Tan, J. W., Dong, Z. J., & Liu, J. K. (2003). New cerebrosides from the basidiomycete Cortinarius tenuipes. Lipids, 38(1), 81–84.PubMedCrossRefGoogle Scholar
  193. Tedesco-Silva, H., Pescovitz, M. D., Cibrik, D., Rees, M. A., Mulgaonkar, S., Kahan, B. D., et al. (2006). Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation, 82(12), 1689–1697. doi: 10.1097/01.tp.0000251718.95622.b3.PubMedCrossRefGoogle Scholar
  194. Thudichum, J. L. W., Simon, J., Thudichum, J. L. W., & St. Thomas’s Hospital. Medical School Library. (1884). A treatise on the chemical constitution of the brain. London: Baillière, Tindall and Cox.Google Scholar
  195. t’Kindt, R., Jorge, L., Dumont, E., Couturon, P., David, F., Sandra, P., et al. (2012). Profiling and characterizing skin ceramides using reversed-phase liquid chromatography-quadrupole time-of-flight mass spectrometry. Analytical Chemistry, 84(1), 403–411. doi: 10.1021/ac202646v.PubMedCrossRefGoogle Scholar
  196. Tolle, M., Pawlak, A., Schuchardt, M., Kawamura, A., Tietge, U. J., Lorkowski, S., et al. (2008). HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(8), 1542–1548. doi: 10.1161/ATVBAHA.107.161042.PubMedPubMedCentralCrossRefGoogle Scholar
  197. Tonelli, F., Lim, K. G., Loveridge, C., Long, J., Pitson, S. M., Tigyi, G., et al. (2010). FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cellular Signalling, 22(10), 1536–1542. doi: 10.1016/j.cellsig.2010.05.022.PubMedPubMedCentralCrossRefGoogle Scholar
  198. Tornquist, K., Blom, T., Shariatmadari, R., & Pasternack, M. (2004). Ceramide 1-phosphate enhances calcium entry through voltage-operated calcium channels by a protein kinase C-dependent mechanism in GH4C1 rat pituitary cells. Biochemical Journal, 380(Pt 3), 661–668. doi: 10.1042/BJ20031637.PubMedPubMedCentralCrossRefGoogle Scholar
  199. Ueda, H., Takahara, S., Azuma, H., Kusaka, M., Suzuki, S., & Katsuoka, Y. (2000). Effect of a novel immunosuppressant, FTY720, on allograft survival after renal transplant in rats. European Surgical Research, 32(5), 279–283.PubMedCrossRefGoogle Scholar
  200. Valsecchi, M., Chigorno, V., Nicolini, M., & Sonnino, S. (1996). Changes of free long-chain bases in neuronal cells during differentiation and aging in culture. Journal of Neurochemistry, 67(5), 1866–1871.PubMedCrossRefGoogle Scholar
  201. Van Overloop, H., Denizot, Y., Baes, M., & Van Veldhoven, P. P. (2007). On the presence of C2-ceramide in mammalian tissues: Possible relationship to etherphospholipids and phosphorylation by ceramide kinase. Biological Chemistry, 388(3), 315–324. doi: 10.1515/BC.2007.035.PubMedGoogle Scholar
  202. Venkataraman, K., Riebeling, C., Bodennec, J., Riezman, H., Allegood, J. C., Sullards, M. C., et al. (2002). Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. Journal of Biological Chemistry, 277(38), 35642–35649. doi: 10.1074/jbc.M205211200.PubMedCrossRefGoogle Scholar
  203. Wang, J., Cheng, A., Wakade, C., & Yu, R. K. (2014). Ganglioside GD3 is required for neurogenesis and long-term maintenance of neural stem cells in the postnatal mouse brain. Journal of Neuroscience, 34(41), 13790–13800. doi: 10.1523/jneurosci.2275-14.2014.PubMedPubMedCentralCrossRefGoogle Scholar
  204. Wang, E., Norred, W. P., Bacon, C. W., Riley, R. T., & Merrill, A. H, Jr. (1991). Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. Journal of Biological Chemistry, 266(22), 14486–14490.PubMedGoogle Scholar
  205. Wang, E., Riley, R. T., Meredith, F. I., & Merrill, A. H, Jr. (1999). Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine. Journal of Nutrition, 129(1), 214–220.PubMedGoogle Scholar
  206. Webb, M., Tham, C. S., Lin, F. F., Lariosa-Willingham, K., Yu, N., Hale, J., et al. (2004). Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. Journal of Neuroimmunology, 153(1–2), 108–121.PubMedCrossRefGoogle Scholar
  207. Welsch, C. A., Hagiwara, S., Goetschy, J. F., & Movva, N. R. (2003). Ubiquitin pathway proteins influence the mechanism of action of the novel immunosuppressive drug FTY720 in Saccharomyces cerevisiae. Journal of Biological Chemistry, 278(29), 26976–26982.PubMedCrossRefGoogle Scholar
  208. Willis, M. A., & Cohen, J. A. (2013). Fingolimod therapy for multiple sclerosis. Seminars in Neurology, 33(1), 37–44. doi: 10.1055/s-0033-1343794.PubMedCrossRefGoogle Scholar
  209. Woodcock, J. M., Ma, Y., Coolen, C., Pham, D., Jones, C., Lopez, A. F., et al. (2010). Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cellular Signalling, 22(9), 1291–1299. doi: 10.1016/j.cellsig.2010.04.004.PubMedCrossRefGoogle Scholar
  210. Xia, P., Gamble, J. R., Wang, L., Pitson, S. M., Moretti, P. A., Wattenberg, B. W., et al. (2000). An oncogenic role of sphingosine kinase. Current Biology, 10(23), 1527–1530.PubMedCrossRefGoogle Scholar
  211. Yamagata, K., Tagami, M., Torii, Y., Takenaga, F., Tsumagari, S., Itoh, S., et al. (2003). Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia, 41(2), 199–206.PubMedCrossRefGoogle Scholar
  212. Yamashita, R., Tabata, Y., Iga, E., Nakao, M., Sano, S., Kogure, K., et al. (2016). Analysis of molecular species profiles of ceramide-1-phosphate and sphingomyelin using MALDI-TOF mass spectrometry. Lipids, 51(2), 263–270. doi: 10.1007/s11745-015-4082-0.PubMedCrossRefGoogle Scholar
  213. Yang, A. H., Ishii, I., & Chun, J. (2002). In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochimica et Biophysica Acta, 1582(1–3), 197–203.PubMedCrossRefGoogle Scholar
  214. Yang, Y., Torta, F., Arai, K., Wenk, M. R., Herr, D. R., Wong, P. T., et al. (2016). Sphingosine kinase inhibition ameliorates chronic hypoperfusion-induced white matter lesions. Neurochemistry International,. doi: 10.1016/j.neuint.2016.02.012.Google Scholar
  215. Yatomi, Y., Ruan, F., Megidish, T., Toyokuni, T., Hakomori, S., & Igarashi, Y. (1996). N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry, 35(2), 626–633. doi: 10.1021/bi9515533.PubMedCrossRefGoogle Scholar
  216. Yu, N., Lariosa-Willingham, K. D., Lin, F. F., Webb, M., & Rao, T. S. (2004). Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia, 45(1), 17–27. doi: 10.1002/glia.10297.PubMedCrossRefGoogle Scholar
  217. Yuan, S., Wu, R., Latek, D., Trzaskowski, B., & Filipek, S. (2013). Lipid receptor S1P(1) activation scheme concluded from microsecond all-atom molecular dynamics simulations. PLoS Computational Biology, 9(10), e1003261. doi: 10.1371/journal.pcbi.1003261.PubMedPubMedCentralCrossRefGoogle Scholar
  218. Zhang, K., Pompey, J. M., Hsu, F. F., Key, P., Bandhuvula, P., Saba, J. D., et al. (2007). Redirection of sphingolipid metabolism toward de novo synthesis of ethanolamine in Leishmania. EMBO Journal, 26(4), 1094–1104. doi: 10.1038/sj.emboj.7601565.PubMedPubMedCentralCrossRefGoogle Scholar
  219. Zitomer, N. C., Mitchell, T., Voss, K. A., Bondy, G. S., Pruett, S. T., Garnier-Amblard, E. C., et al. (2009). Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: A novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. Journal of Biological Chemistry, 284(8), 4786–4795. doi: 10.1074/jbc.M808798200.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Pharmacology, Yong Loo Lin School of MedicineNational University of SingaporeKent RidgeSingapore
  2. 2.Department of Biochemistry, Yong Loo Lin School of MedicineNational University of SingaporeKent RidgeSingapore
  3. 3.Department of BiologySan Diego State UniversitySan DiegoUSA
  4. 4.Department of Molecular and Cellular Neuroscience, Dorris Neuroscience CenterThe Scripps Research InstituteLa JollaUSA

Personalised recommendations